Our study showed that USP1 knockdown delayed the growth of tumors in the RL-4RH cells-derived xenotransplantation mouse model of DLBCL, which suggested that USP1 is a potential therapeutic target for rituximab/chemotherapy resistant DLBCL. The gene discussed is USP1; the disease is diffuse large B-cell lymphoma.